banner technology

What challenges does Oncosema tackle?

Even though the monitoring of CTC rates in blood is an efficient biomarker to give real-time insights into cancer development, CTC remain exceedingly rare events among all the peripheral blood cells. 

Oncosema patented technology can specifically capture and detect CTC in extremely complex environments.

Why is Oncosema technology innovative?

We own an exclusive license of a patent, describing an innovative method for the detection of CTC using specific antibodies targeting surface glycan markers, also known as TACA for Tumor Associated Carbohydrate Antigens.

Oncosema technology:

  • Specificity

    Targets TACA that are exclusively present on CTC (and totally absent from regular cells).
  • Sensitivity

    Efficiently detects all CTC subtypes, whether they are epithelial, mesenchymal, or involved in epithelial-mesenchymal transition.
  • Broad spectrum

    Sorts CTC shed by tumor from any organ.
  • Preserve viability

    Preserves CTC viability, allowing various analyses.
bandeau technology

How does it work?

1 - Viable CTC sorting

CTC are selectively captured from whole blood by magnetic particles coated with anti-TACA antibodies. Thanks to a magnet, CTC-beads complexes are isolated from all other blood cells. CTC are removed from beads using specific enzymes: they are released in a small volume of elution buffer, allowing their concentration.

LEARN MORE about Oncosema products

2 - Downstream analyses

Oncosema technology opens up many possibilities following CTC sorting :


using either an automated immunoassay system or a slide scanner

Spheroïde culture


  • Genomic sequencing
  • Proteomic analysis
  • Multi-drug resistance
  • Stemness analyses
  • Chemotherapeutic drugs sensitivity